Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

A vial of AstraZeneca's COVID-19 vaccine, in Gragnague, France, on Feb. 26, 2021.

FRED SCHEIBER/AFP/Getty Images

Canada hit a new daily record and passed a new milestone for vaccinations this week but will need to up its game to get a single dose to every eligible person by Canada Day.

It’s doable on paper but potential barriers loom. Export controls in Europe and India and the risk of production issues for brand-new vaccines are among them, along with ongoing fears that anxious Canadians will reject the troubled Oxford-AstraZeneca vaccine.

The number of people vaccinated with at least one dose topped five million as of Thursday morning, leaving about 27 million people over 16 still needing a first dose. About 1.4 million doses are needed to add kids between 12 and 15, who should soon be eligible to get the Pfizer-BioNTech vaccine after a successful trial concluded this week.

Story continues below advertisement

Current projections are that Canada will receive between 32 and 36 million doses of Pfizer, Moderna and the Oxford-AstraZeneca vaccine before June 30.

Provinces and territories injected nearly 220,000 doses of vaccine Wednesday, besting their previous record of 217,000 set five days earlier. They averaged more than 185,000 doses a day over the past seven days, the highest seven-day average to date.

They will need to average somewhere between 310,000 and 330,000 doses a day to get one dose to all Canadians 12 years of age and older over the next three months.

Howard Njoo, deputy chief public-health officer, said almost three in four Canadians over the age of 80 have now received at least one dose, and so have nearly one-third of people between 70 and 79 years old.

“What we are seeing in terms of vaccine rollout is encouraging,” Dr. Njoo said.

But the risks of problems continue. The delivery of 590,000 doses of Moderna vaccine was delayed almost a week after a backlog in quality-assurance checks in Europe. Those doses were supposed to arrive March 27, but didn’t leave Europe by plane until Thursday.

Major-General Dany Fortin, the military commander co-ordinating the vaccine rollout for the Public Health Agency of Canada, said provinces should start getting them on Saturday.

Story continues below advertisement

Europe’s increased export controls haven’t yet prevented shipments to Canada but approvals are needed by the European Commission every week for the shipments to continue. That includes 17.8 million Pfizer doses and 12.3 million Moderna doses expected in the next three months.

Joelle Paquette, director-general in charge of vaccines at Public Services and Procurement Canada, said Thursday that India’s ban on exports from the Serum Institute of India will delay Canada’s April shipment of the AstraZeneca vaccine from there. Canada is expecting one million doses in April and 500,000 in May. Ms. Paquette said the doses will come eventually but she couldn’t put a date on it now.

She said she didn’t expect an impact from a problem with Johnson & Johnson’s manufacturing that forced the company to toss 15 million doses this week after a mix-up at a Maryland production facility.

Ms. Paquette said Canada doesn’t know yet where its J&J doses are being made yet but said the U.S. issue won’t affect Canada.

Maj.-Gen. Fortin said the first 300,000 doses from the international vaccine-sharing program known as COVAX are expected next week, and Canada is supposed to get another 1.6 million of those by the end of June.

The COVAX doses are AstraZeneca vaccine made in South Korea, and will be in addition to the 1.5 million AstraZeneca doses provinces started receiving Thursday from the United States.

Story continues below advertisement

Health Canada authorized the manufacturing facilities for those doses Wednesday, clearing the way for them to be distributed.

It remains to be seen how many Canadians will be eager to get them after the roller coaster of confusion surrounding that vaccine. That includes this week’s decision by every province to stop using it on people under the age of 55 while Health Canada waits for more data on the risk of blood clots.

Provinces have already doled out more than 85 per cent of the first 500,000 Serum Institute doses of AstraZeneca shipped in March, and Maj.-Gen. Fortin said he believed all the doses that expire Friday have been used.

Some provinces reported issues with cancellations for vaccine appointments following the AstraZeneca pause, but there are also signs that giving them out won’t be that hard.

Long lineups formed outside pharmacies in the Vancouver area Wednesday when AstraZeneca injections began there for people 55 to 65 years old.

Ontario is ramping up its AstraZeneca rollout this weekend, doubling the number of pharmacies that will get it, and expanding the age to 55 to 64 years old from 60 to 64.

Story continues below advertisement

One positive report Thursday is that provinces have had no trouble getting six doses out of every vial of Pfizer instead of five. Health Canada adjusted the number of doses per vial at Pfizer’s request in February, but getting the extra doses requires the use of a special syringe that lets less vaccine go to waste.

Maj.-Gen. Fortin said provinces have been sent 15 million of those syringes so far, and report being able to get the sixth dose out more than 98 per cent of the time.

Prime Minister Justin Trudeau says Pfizer is increasing its vaccine delivery schedule, adding five million doses to June shipments for a total of 9.6 million doses that month. This is in addition to expected shipments of two other vaccines. The Canadian Press

Sign up for the Coronavirus Update newsletter to read the day’s essential coronavirus news, features and explainers written by Globe reporters and editors.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies